Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Mike Stratton, Harold Davies, Antony Peake, Samuel Colella, Gajus Worthington


Mike Stratton, director of the Wellcome Trust Sanger Institute, has been knighted in the UK. Stratton founded the Cancer Genome Project at the Sanger Institute, leading the team that discovered mutations in the BRAF gene in malignant melanoma. In 2009, his team published the first full genome sequencing of two tumors, a lung cancer and a malignant melanoma. Early in his career, he discovered the BRCA2 breast cancer susceptibility gene.

Harold Davies has been appointed CFO of the J. Craig Venter Institute, where he will report to CEO Craig Venter. Antony Peake has been hired as director of sponsored projects, effective July 1, and will report to Davies.

For the past eight years Davies was CFO at the Donald Danforth Plant Science Center. Previously he was corporate controller for Alper Ink and also worked as the director of financial planning and analysis for Huttig Building Products. He is a Certified Public Accountant with an MBA from Washington University in St. Louis.

Peake joins JCVI from Sanford-Burnham Medical Research Institute, where he was director of grants accounting. Previously, he held positions at the University of Cambridge in the UK. He is a certified research administrator with a degree in business administration from the University of Cambridge.

Fluidigm has re-elected Samuel Colella and Gajus Worthington to serve as class III directors until the firm's 2016 stockholder meeting. Colella, who is a managing director of Versant Ventures, has been a member and chairman of the company's board since 2000.

Worthington is the company's president, CEO, and co-founder, and he has been a director since the firm launched in 1999.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.